SIM
DNLI icon

Spark Investment Management’s Denali Therapeutics DNLI Stock Holding History

Spark Investment Management’s Portfolio DNLI Stock Details DNLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-22,700
Closed -$527K – 602
2019
Q1 		$527K Buy
+22,700
New +$475K 0.02% 403

Other funds holding DNLI

CM
Crestline Management Fort Worth, Texas $53.5M AUM 80.67% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.54B AUM 86.39% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $34.9B AUM 72.7% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

Spark Investment Management's DNLI Position: Q2 2019 in Review

Spark Investment Management sold out of Denali Therapeutics (DNLI) in Q2 2019, closing a stake of 22,700 shares — an estimated $527K sold.

Spark Investment Management first reported a position in DNLI in Q1 2019 and held it in 1 quarter. The position peaked at $527K in Q1 2019. 114 funds tracked by Wall St. Rank hold DNLI as of Q2 2019.

  • Spark Investment Management reported no remaining Denali Therapeutics position as of Q2 2019 after selling out during the quarter.
  • Spark Investment Management sold 22,700 Denali Therapeutics shares in Q2 2019, an estimated $527K.
  • Spark Investment Management first reported a position in Denali Therapeutics in Q1 2019 and held it in 1 quarter.
  • Spark Investment Management's Denali Therapeutics position peaked at $527K in Q1 2019.
  • 114 funds tracked by Wall St. Rank held Denali Therapeutics as of Q2 2019.

Based on Spark Investment Management's 13F filing for Q2 2019, filed 12 Aug 2019.